Navigation Links
Nektar Therapeutics Reports First Quarter 2009 Financial Results
Date:5/6/2009

Property and equipment, net 75,020 73,578 Goodwill 76,501 76,501 Other assets 3,823 4,237 ----- ----- Total assets $505,939 $560,536 ======== ======== LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $2,675 $13,832 Accrued compensation 5,437 11,570 Accrued clinical trial expenses 14,982 17,622 Accrued expenses 11,583 9,923 Deferred revenue, current portion 8,416 10,010 Interest payable 58 1,805 Other current liabilities 3,486 3,612 ----- ----- Total current liabilities 46,637 68,374 Convertible subordinated notes 214,955 214,955 Capital lease obligations 19,989 20,347 Deferred revenue 54,132 55,567 Deferred gain 5,682 5,901 Other long-term liabilities 5,270 5,238 ----- ----- Total liabilities 346,665 370,382 Commitments and contingencies Stockholders' equity: Preferred stock - - Common stock 9 9 Capital in excess of par value 1,315,182 1,312,796 Accumulated other comprehensive income (loss) (20) 1,439
'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
2. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
3. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
4. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
5. Nektar Therapeutics President and CEO Howard Robin to Present at 2007 BIO InvestorForum
6. Nektar Therapeutics to Present at 2007 BMO Capital Markets Focus on Healthcare Conference
7. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
8. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
9. Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
10. West Concludes Agreement with Nektar
11. Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... , April 16, 2015  AnaptysBio, Inc., ... of therapeutic antibodies, today announced the advancement ... program into IND-enabling studies. The Company,s anti-IL-36R ... treatment for generalized pustular psoriasis (GPP), an ... medical need. ANB019 is wholly owned within AnaptysBio,s ...
(Date:4/16/2015)... , April 16, 2015 Avelas Biosciences, an ... improving cancer surgeries, announced today that it has initiated ... illuminator, AVB-620, in women with primary, non-recurrent breast cancer ... also welcomed the addition of Steven Chen , ... The open label, dose escalation study will enroll up ...
(Date:4/16/2015)... Switzerland , April 16, 2015 /PRNewswire/ ... Debiopharm Group ™ , a Swiss-based global biopharmaceutical ... medical needs as well as companion diagnostics, ... investigational compounds Debio 1143 (SMAC mimetic) and Debio 1347/CH5183284 ... the 2015 Annual meeting of the American Association for Cancer Research ...
(Date:4/16/2015)... Fairleigh Dickinson University ( FDU ... become the Executive Director of the Rothman Institute ... kick-off of the Initiative for Patient Centered Innovation ... under the Rothman Institute of Innovation and Entrepreneurship ... collaboration with FDU’s School of Pharmacy’s Center for ...
Breaking Biology Technology:AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3
... out of the desert floor at a place called Ash Meadows, ... found nowhere else in the world. A new Brigham Young ... completing a 15,000-year journey, flowing slowly underground from what is now ... there for four decades, and a crack in the Earth,s crust ...
... , June 17 On Friday June 11th , ... for the District of Delaware issued an important pre-trial ruling ... , , , ... defined several key phrases contained in Roquette,s patent claims, thereby dealing a ...
... ... have demonstrated its ability to diminish or eliminate tumor load in melanoma, breast cancer, colon ... ... Inc., a regenerative medicine company developing solutions based on the products of newborn cells grown ...
Cached Biology Technology:SPI Pharma Gains Ground in Roquette Patent Dispute 2Human Embryonic-Like Extracellular Matrix Significantly Inhibits Tumor Growth and Cancer Cell Proliferation 2Human Embryonic-Like Extracellular Matrix Significantly Inhibits Tumor Growth and Cancer Cell Proliferation 3
(Date:3/24/2015)... March 24, 2015   NexID Biometrics LLC, ... security-authentication needs, today announced the beginning of shipments of ... The company, based in Potsdam, ... three-day Connect:ID Expo, which began here today at the ... version 2.0 of its SDK boosts the accuracy rate ...
(Date:3/23/2015)... Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... on CNBC television starting March 30 th . ... in New York markets. ... are excited about our new ad campaign following the recent ...
(Date:3/19/2015)... , March 19, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces its ... a news clip that aired this week on ... . In a segment "The Next Great Thing", ... ,a new way to pay, and ,a really big breakthrough ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... fight against the deadly Hendra virus following the development of ... of people who become infected with the virus. ... that administering human monoclonal antibodies after exposure to Nipah virus, ... challenge in a disease model. According to CSIRO,s Dr ...
... SCM Microsystems, Inc. (Nasdaq: SCMM ) (Prime Standard: ... identity and secure exchange, announced today that its stockholders have ... during yesterday,s annual meeting of stockholders. , At ... of SCM,s stockholders cast their votes and a majority followed ...
... that around 2.4 billion years ago, the Earth,s atmosphere ... Called the "Great Oxidation Event" (GOE), the oxygen ... transformation from an oxygen-poor atmosphere to an oxygen-rich one ... the planet. Two questions that remain unresolved in ...
Cached Biology News:Breakthrough in fight against Hendra virus 2SCM Microsystems Announces Results of Annual Meeting 2A new wrinkle in ancient ocean chemistry 2A new wrinkle in ancient ocean chemistry 3
... The Luminex 100 IS System is a ... laboratory that integrates lasers, optics, fluidics, a controller, ... reader. This powerful, compact lab analysis system includes ... SD. Also, it has a DMF file at ...
... Highly nutritious peptone, ... the production of bacterial ... cultivation of bacteria with ... Corynbacterium, Haemophilus, Neisseria, Pasteurella, ...
... A549 cells were cultured in Ham's F12K medium ... log phase of growth. In order to keep ... fixed in acetone-methanol. The cells are arrayed on ... each wells surface specifically treated to enhance cellular ...
Cell Culture Flask, 175 cm, tissue-culture treated polystyrene, barcoded...
Biology Products: